Fluoxetine in social phobia: A double-blind, placebo-controlled pilot study

Journal of Clinical Psychopharmacology

Volumn 22, Issue 3, 2002, Pages 257-262

  Kobak, Kenneth A ^a   Greist, John H ^a   Jefferson, James W ^a   Katzelnick, David J ^a  

^a Healthcare Technology Systems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BROFAROMINE; CITALOPRAM; CORTICOSTEROID; FLUOXETINE; FLUVOXAMINE; MOCLOBEMIDE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRYPTOPHAN;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NERVOUSNESS; PRIORITY JOURNAL; RATING SCALE; SINGLE BLIND PROCEDURE; SOCIAL PHOBIA;

ADOLESCENT; ADULT; AGED; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PHOBIC DISORDERS; PILOT PROJECTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0036113828     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200206000-00005     Document Type: Article

References (55)

1. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey
2. Social phobia: A comparative clinical study
3. Moving away from the world: Lifecourse patterns of shy children
4. Impact of social anxiety disorder in managed care patients
5. Shyness and dysfunction in career development
6. Syndrome comorbidity in patients diagnosed with a DSM-III Revised anxiety disorder
7. Social phobia: Comorbidity and morbidity in an epidemiologic sample
8. Delineating social phobia
9. Situational determinants of social anxiety in clinic and nonclinic samples: Physiological and cognitive correlates
10. Quality of life in social phobia
11. Social phobia: A pharmacologic treatment overview
12. Psychopharmacological treatment of social phobia: A double blind placebo controlled study with fluvoxamine
13. Fluvoxamine treatment of social phobia (social anxiety disorder): A double-blind, placebo-controlled study
14. Sertraline for social phobia: A double-blind, placebo-controlled crossover study
15. Sertraline treatment of generalized social phobia: A 20-week, double-blind, placebo-controlled study
16. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia
17. Citalopram in the treatment of social phobia: A report of three cases
18. Paroxetine in social phobia/social anxiety disorder: Randomised, double-blind, placebo-controlled study
19. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial
20. Venlafaxine in social phobia: A study in selective serotonin reuptake inhibitor non-responders
21. Venlafaxine in social phobia
22. A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders
23. Does tryptophan potentiate clomipramine in the treatment of agoraphobic and social phobic patients?
24. Dimensional versus categrical response to moclobemide in social phobia
25. Social phobia: The clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine
26. Moclobemide in social phobia: A double-blind, placebo-controlled clinical study
27. Brofaromine for social phobia: A multi-center, placebo-controlled, double-blind study
28. Psychopharmacological treatment of social phobia: Clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor
29. Pharmacotherapy of social phobia, a controlled study with moclobemide and phenelzine
30. Treatment of social phobia with gabapentin: A placebo-controlled study
31. Fluoxetine treatment of social phobia
32. Fluoxetine in social phobia
33. Fluoxetine for the treatment of social phobia
34. Fluoxetine efficacy in social phobia
35. Treatment of social phobia with fluoxetine
36. Open fluoxetine treatment of mixed anxiety disorders in children and adolescents
37. Social phobia
38. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive compulsive disorder
39. Brief standard self-rating for phobic patients
40. The assessment of anxiety states by rating
41. The brief social phobia scale
42. A rating scale for depression
43. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance
44. The MOS 36-item short-form general health survey (SF-36), I: Conceptual framework and item selection
45. Computer interview assessment of social phobia in a clinical drug trial
46. Placebo-controlled trial of moclobemide in social phobia
47. Moclobemide in social phobia: A double-blind, placebo-controlled clinical study
48. Moclobemide in social phobia: A controlled dose-response trial
49. Phenelzine vs atenolol in social phobia: A placebo-controlled comparison
50. Treatment of social phobia with clonazepam and placebo
51. Concerns about clinical trials
52. A risk-benefit assessment of pharmacological treatments for panic disorder
53. Further evidence that a placebo response to antidepressants can be identified